Clinical trials: Solid Malignant Tumor
Solid Tumor
A Study of Nivolumab in Combination With Ipilimumab in Chinese Participants With Previously Treated Advanced or Recurrent Solid Tumors
The purpose of this study is to evaluate the safety and effectiveness of Nivolumab in combination with Ipilimumab in Chinese participants with previously treated late stage cancer.
- Trial name
- NCT03195478
- Testing
- Nivolumab, Ipilimumab
- Where
- 12 sites in China
- Volunteers
- 37 people
- Sponsor
- Bristol-Myers Squibb
Tumor, Solid, Tumor
Dose-escalation Study to Assess Safety and Pharmacokinetics of Nab-Sirolimus in Patients With Locally Advanced or Metastatic Solid Tumors and Moderate Liver Impairment
This is a phase 1, multi-center, open-label, dose-escalation study of nab-sirolimus in adult patients with locally advanced or metastatic solid tumors and moderate hepatic impairment or normal hepatic function.
- Conditions
- Tumor, Solid, Tumor, Advanced Solid Tumor
- Trial name
- NCT05661461
- Testing
- nab-sirolimus
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Aadi Bioscience, Inc.
Pancreatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
ABC294640 in Treating Patients With Advanced Solid Tumors
This phase I trial studies the side effects and best dose of ABC294640 in treating patients with advanced solid tumors. ABC294640 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Trial name
- ABC-101 (NCT01488513)
- Testing
- sphingosine kinase-2 inhibitor ABC294640
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- RedHill Biopharma Limited
Solid Tumor, KRAS Mutation-Related Tumors
A Study of ZG2001 in Participants With KRAS Mutated Advanced Solid Tumours
This study will evaluate the tolerability, safety, effects, and pharmacokinetics of ZG2001 in Participants with advanced solid tumors that have a KRAS mutation.
- Trial name
- NCT06237413
- Testing
- ZG2001 Tosilate Tablets
- Where
- China
- Volunteers
- 110 people
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Advanced Solid Tumors
Effect of High-fat Meal on the Pharmacokinetics of TQ-B3139 Capsules
This is a study to evaluate the effect of high-fat meal on the pharmacokinetics of TQ-B3139 capsules in patients with solid tumor
- Trial name
- NCT04675060
- Testing
- TQ-B3139 capsules
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Solid Tumor, Adult, BRCA1 Mutation
Study of ACE-86225106 to Treat Patients With Advanced Solid Tumors
The purpose of this study is to determine if the experimental treatment with poly-ADP ribose polymerase (PARP) inhibitor, ACE-86225106 is safe, tolerable and has anti-cancer activity in adult patients with advanced solid tumors.
- Conditions
- Solid Tumor, Adult, BRCA1 Mutation, BRCA2 Mutation, Ovarian Cancer
- Trial name
- NCT06380660
- Testing
- ACE-86225106 tablet
- Where
- 14 sites in China
- Volunteers
- 298 people
- Sponsor
- Acerand Therapeutics (Shanghai) Limited
Advanced Cancer, Advanced Solid Tumor
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
This study is an open-label Phase Ib (Part A) dose escalation followed by a blinded, randomized, multi cohort Phase 2a (Part B) comparison of combination vs. reference regimens.
- Conditions
- Advanced Cancer, Advanced Solid Tumor, Melanoma, Metastasis
- Trial name
- NCT06362369
- Testing
- Alintegimod, Ipilimumab, Nivolumab
- Where
- 5 sites in United States
- Volunteers
- 126 people
- Sponsor
- 7 Hills Pharma, LLC
Advanced Solid Tumor
A Food Effect Study of SPH5030 Tablets.
The purpose of this study is to evaluate the food effect of SPH5030 tablets in healthy Chinese adult subjects.
- Trial name
- NCT06372223
- Testing
- SPH5030
- Where
- China
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Shanghai Pharmaceuticals Holding Co., Ltd
Advanced Solid Tumor
A Study of QLF3108 in Participants With Advanced Solid Tumor
This study will evaluate the safety, tolerability, pharmacokinetics, and immunogenicity of QLF3108 and will make a preliminary assessment of the anti-tumor activity of QLF3108 in patients with advanced solid tumor.
- Trial name
- NCT06019013
- Testing
- QLF3108
- Where
- China
- Volunteers
- 78 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Solid Tumor, Melanoma
A Study of TRK-950 in Patients With Advanced Solid Tumors
Part 1 To determine the safety and tolerability of TRK-950 in patients with advanced solid tumors Part 2 To determine the safety and tolerability of TRK-950 in combination with nivolumab(NIVO) in patients with advanced solid…
- Trial name
- NCT05423262
- Testing
- TRK-950, Nivolumab
- Where
- 10 sites in Japan
- Volunteers
- 49 people
- Sponsor
- Toray Industries, Inc
Advanced Solid Tumors, Metastatic Melanoma
Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors
This is an open-label, 3-arm, fixed-sequence study to evaluate the effect of single and multiple oral doses of encorafenib in combination with binimetinib on the single oral dose pharmacokinetics (PK) of cytochrome P450 (CYP)…
- Trial name
- NCT03864042
- Testing
- losartan, dextromethorphan, caffeine
- Where
- 29 sites in United States, Belgium and 3 more
- Volunteers
- 56 people
- Sponsor
- Pfizer
Advanced Malignant Solid Tumor
A Study of MHB118C Injection in Patients With Advanced Solid Tumors
This is a first-in-human, open-label, multicenter Phase I study of MHB118C in patients with advanced solid tumors. The study was designed to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of…
- Trial name
- NCT07045454
- Testing
- MHB118C for Injection
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Minghui Pharmaceutical (Hangzhou) Ltd
Malignant Solid Tumor
A Trial of AVID200, a Transforming Growth Factor β (TGFβ) Inhibitor, in Patients Malignancies
TGFβ has profound local immunosuppressive and immunoexclusion effects in the tumor microenvironment that are integrally involved in the failure of immune checkpoint inhibitors in some tumors.
- Trial name
- NCT03834662
- Testing
- AVID200
- Where
- 3 sites in United States, Canada
- Volunteers
- 19 people
- Sponsor
- Bristol-Myers Squibb
Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Cancer
A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor
This is an open-label, Phase I, dose escalation study to determine the recommended Phase 2 dose, maximum tolerated dose, and evaluate the safety and pharmacokinetic profile of ABBV-221 in participants with advanced solid tumors…
- Conditions
- Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Cancer, Triple Negative Breast Cancer, Colorectal Carcinoma
- Trial name
- NCT02365662
- Testing
- ABBV-221
- Where
- 5 sites in United States, Spain
- Volunteers
- 46 people
- Sponsor
- AbbVie
Advanced Breast Cancer, Advanced Malignant Solid Tumor
A Study of MHB036C Combined With MHB039A in Patients With Advanced Breast Cancer or Other Advanced Malignant Solid Tumors
This is an open-label, multicenter Phase II study of MHB036C combined with MHB039A in patients with advanced Breast Cancer or other advanced malignant solid tumors.
- Trial name
- NCT07130383
- Testing
- MHB036C for Injection, MHB039A for Injection
- Where
- China
- Volunteers
- 210 people
- Sponsor
- Minghui Pharmaceutical (Hangzhou) Ltd
Cancer
Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma
RATIONALE: Intravenous VEGF Trap may stop the growth of solid tumors or non-Hodgkin's lymphoma by stopping blood flow to the cancer.
- Trial name
- NCT00082823
- Testing
- ziv-aflibercept
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Regeneron Pharmaceuticals
Advanced or Metastatic Solid Tumor, Liver Failure
Study of Sacituzumab Govitecan in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment
The goals of this clinical study are to learn more about the safety and dosing of the study drug, sacituzumab govitecan-hziy, in participants with solid tumors and moderate liver problems.
- Trial name
- NCT04617522
- Testing
- Sacituzumab Govitecan-hziy
- Where
- 15 sites in United States, France and 2 more
- Volunteers
- 30 people
- Sponsor
- Gilead Sciences
Solid Tumor
A Clinical Study of HRS-8364 in the Treatment of Advanced Solid Tumor Subjects
This study is an open, multicenter, Phase I/II clinical trial, divided into three stages: dose escalation, dose expansion and efficacy expansion.
- Trial name
- NCT07446153
- Testing
- HRS-8364 Tablet
- Where
- 2 sites in China
- Volunteers
- 282 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Head and Neck Squamous Cell Carcinoma, Soft Tissue Sarcoma Adult
A Phase 0 Multicenter Study of the Pharmacodynamic Effects of Intratumoral Microdose Administration of PBA-0111 in Patients With Solid Tumors
This is a multi-center, single arm, open-label, localized pharmacodynamic biomarker Phase 0 trial designed to study the biological effects within the tumor microenvironment of PBA-0111 when administered intratumorally in…
- Conditions
- Head and Neck Squamous Cell Carcinoma, Soft Tissue Sarcoma Adult, Triple Negative Breast Cancer
- Trial name
- NCT06700070
- Testing
- PBA-0111
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Pure Biologics S.A.
Lung Cancer (NSCLC), Prostate Cancer
A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of TJ101 in Patients With Advanced/Metastatic Solid Tumors
The goal of this clinical trial is to evaluate whether TJ101, an investigational antibody-drug conjugate (ADC), can safely and effectively treat patients with advanced solid tumors.
- Conditions
- Lung Cancer (NSCLC), Prostate Cancer, Esophageal Cancer, Solid Tumor Malignancies
- Trial name
- NCT07181473
- Testing
- TJ101
- Where
- 7 sites in United States, China
- Volunteers
- 200 people
- Sponsor
- Phrontline Biopharma
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.